# FDA 483 - Cipla, Ltd. - May 08, 2024

Source: https://www.keypedia.com/records/483/cipla-ltd/49e75f7a-9d48-4aab-b5d8-fcdacd62e11c

> FDA 483 for Cipla, Ltd. on May 08, 2024. Product: N/A. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Cipla, Ltd.
- Inspection Date: 2024-05-08
- Office Name: Office of Pharmaceutical Quality Operations
- Summary: This FDA Form 483 document outlines observations made during an inspection of a pharmaceutical manufacturing facility. The inspection identified three key deficiencies related to quality systems and manufacturing controls.

Observation 1 notes the firm's failure to establish an adequate system for monitoring environmental conditions within the aseptic processing area. This indicates a potential risk to product sterility and patient safety, as environmental controls are critical in aseptic manufacturing to prevent contamination.

Observation 2 highlights that the firm did not adequately validate the sterilization process for production equipment. Proper validation ensures that equipment is consistently sterilized to eliminate microbial contamination, which is essential for maintaining product quality and safety, particularly for sterile products.

Observation 3 states that the firm did not conduct routine calibration of critical equipment used in the manufacturing process. The lack of routine calibration can lead to inaccurate measurements and process deviations, potentially impacting product quality, potency, and purity.

These observations collectively point to deficiencies in the firm's quality management system, specifically concerning environmental monitoring, process validation, and equipment calibration. Addressing these issues is crucial for the firm to ensure compliance with Good Manufacturing Practices (GMP) and maintain the quality and safety of its manufactured products.

## Related Documents

- [483 - 2018-11-30](https://www.keypedia.com/records/483/cipla-ltd/c2182f72-76c8-4eda-b528-fd5f65155e44)
- [483 - 2018-11-30](https://www.keypedia.com/records/483/cipla-ltd/073508e0-bb26-49d8-a957-16fbe67ca9f6)
- [483 - 2019-03-20](https://www.keypedia.com/records/483/cipla-ltd/4f536fa1-9193-4e02-8c65-9f726b4bc1da)
- [483 - 2024-05-06](https://www.keypedia.com/records/483/cipla-ltd/7c8e1395-291d-4698-ad4d-88a7bde50b11)

## Related Officers

- [Santos E. Camara](https://www.keypedia.com/people/santos-e-camara/18cea942-f6f9-4dec-9ce9-1c01c39009ce)
- [Xin Li](https://www.keypedia.com/people/xin-li/8021b79a-7689-4826-8bf9-52d92a16060c)

Company: https://www.keypedia.com/companies/cipla-ltd/f726d9c8-4fe7-456e-848c-f9ef86f00e4f

Office: https://www.keypedia.com/offices/office-of-pharmaceutical-quality-operations/6b0153a9-c1d1-46a5-8b10-836d2ae44ffe